drugset / Trial / NCT06740799
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate and compare the PK in subjects with severe HI to that of matched healthy control subjects with normal hepatic function.
Timeline
- Start
- 2024-09-30
- Primary completion
- 2026-10-31
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quizartinib | Small molecule | 30 mg | Oral |
Indications
No indication recorded.